Technical Analysis for BGNE - BeiGene, Ltd.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| See historical BGNE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Aug 17 | Lower Bollinger Band Walk | Weakness | 0.00% |
| Aug 17 | Multiple of Ten Bearish | Other | 0.00% |
| Aug 17 | Oversold Stochastic | Weakness | 0.00% |
| Aug 16 | NR7 | Range Contraction | 0.12% |
| Aug 16 | Doji - Bullish? | Reversal | 0.12% |
| Aug 16 | Lower Bollinger Band Walk | Weakness | 0.12% |
| Aug 16 | Multiple of Ten Bearish | Other | 0.12% |
| Aug 16 | Lower Bollinger Band Touch | Weakness | 0.12% |
| Aug 16 | Oversold Stochastic | Weakness | 0.12% |
| Aug 15 | 180 Bearish Setup | Bearish Swing Setup | -0.23% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-08-08
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more BGNE news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 220.1 |
| 52 Week Low | 65.67 |
| Average Volume | 333,977 |
| 200-Day Moving Average | 145.3678 |
| 50-Day Moving Average | 169.586 |
| 20-Day Moving Average | 171.4525 |
| 10-Day Moving Average | 166.038 |
| Average True Range | 8.1716 |
| ADX | 17.68 |
| +DI | 15.4842 |
| -DI | 26.0233 |
| Chandelier Exit (Long, 3 ATRs ) | 170.0452 |
| Chandelier Exit (Short, 3 ATRs ) | 179.5248 |
| Upper Bollinger Band | 189.0367 |
| Lower Bollinger Band | 153.8683 |
| Percent B (%b) | 0.1 |
| BandWidth | 20.512037 |
| MACD Line | -3.2559 |
| MACD Signal Line | -1.0534 |
| MACD Histogram | -2.2025 |
| Fundamentals | Value |
|---|---|
| Market Cap | 6.27 Billion |
| Num Shares | 39.8 Million |
| EPS | -4.97 |
| Price-to-Earnings (P/E) Ratio | -31.65 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 12.46 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 166.86 | ||||
| Resistance 3 (R3) | 167.32 | 164.60 | 165.27 | ||
| Resistance 2 (R2) | 164.60 | 162.17 | 164.37 | 164.74 | |
| Resistance 1 (R1) | 160.96 | 160.67 | 159.60 | 160.50 | 164.21 |
| Pivot Point | 158.24 | 158.24 | 157.56 | 158.01 | 158.24 |
| Support 1 (S1) | 154.60 | 155.81 | 153.24 | 154.14 | 150.43 |
| Support 2 (S2) | 151.88 | 154.31 | 151.65 | 149.90 | |
| Support 3 (S3) | 148.24 | 151.88 | 149.37 | ||
| Support 4 (S4) | 147.78 |
